View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 5, 2021

GSK signs agreement with Canada to supply Covid-19 drug

The deal allows Canada's provincial and territorial healthcare systems to use sotrovimab from this month.

GlaxoSmithKline (GSK) has signed an agreement with the government in Canada to supply Covid-19 monoclonal antibody therapy, Sotrovimab.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Developed together with Vir Biotechnology, Sotrovimab is an investigational single-dose SARS-CoV-2 antibody.

It is intended to treat adults and adolescent Covid-19 patients aged 12 years and above who do not require oxygen supplementation but may progress to severe disease.

According to the deal, the company will supply 10,000 doses of Sotrovimab for injection to Canada.

GSK said that the agreement allows Canada’s provincial and territorial healthcare systems to use sotrovimab from this month.

GSK Canada Government Affairs and Market Access head Ranya El Masri said: “With the emergence of variants of concern across the country, in particular the Delta variant, new therapies like sotrovimab are important to treating the disease in its early stages.

“GSK is proud to partner with the Government of Canada to help ensure Canadians can access sotrovimab, particularly those who will benefit from this treatment the most such as older adults and individuals with certain chronic medical conditions that could put them at higher risk of hospitalisation or death due to Covid-19.”

The agreement also includes an option for the government to acquire additional doses next year depending on the emerging requirements.

The drug was approved by Health Canada under its Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to Covid-19 in July.

During the same month, the company along with its partner Vir Biotechnology signed a joint procurement agreement with the European Commission (EC) to supply up to 220,000 sotrovimab doses.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology